The Breast Cancer Screening Market is predicted to reach US$ by 2030 from US$ 2.50 billion in 2021, and to grow at a CAGR of 6.7% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Type (Mammography, MRI [Magnetic Resonance Imaging], Ultrasound, Tomography, Genome Test, and Biopsy), by Product (Instrument-based Product [Biopsy and Imaging] and Platform-based Product [PCR (Polymerase Chain Reaction), Next-generation Sequencing, Microarrays, and Others]), and by End User (Hospitals, Diagnostic Centers, and Cancer Institutes)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
BioTime Inc., Siemens Healthcare Diagnostics Inc., A&G Pharmaceutical Inc., POC Medical
Systems Inc., Biocrates Life Sciences AG, Hologic Inc., OncoCyte Corporation, Metabolomic Technologies Inc., Myriad Genetics Inc., and Koninklijke Philips N.V. among others
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Breast Cancer Screening - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Breast Cancer Screening - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Breast Cancer Screening - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Breast Cancer Screening - ANALYSIS & FORECAST, BY REGION
North America Breast Cancer Screening
1. North America Breast Cancer Screening , by Country
1. US
2. Canada
1. North America Breast Cancer Screening , by Product
2. North America Breast Cancer Screening , by Type
3. North America Breast Cancer Screening , by Gender
4. North America Breast Cancer Screening , by Sales Channel
3. Europe Breast Cancer Screening
1. Europe Breast Cancer Screening , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Breast Cancer Screening , by Product
3. Europe Breast Cancer Screening , by Type
4. Europe Breast Cancer Screening , by Gender
5. Europe Breast Cancer Screening , by Sales Channel
4. Asia Pacific Breast Cancer Screening
1. Asia Pacific Breast Cancer Screening , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Breast Cancer Screening , by product
3. Asia Pacific Breast Cancer Screening , by Type
4. Asia Pacific Breast Cancer Screening , by Gender
5. Asia Pacific Breast Cancer Screening , by Sales Channel
5. Rest of the World Breast Cancer Screening
1. Rest of the World Breast Cancer Screening , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Breast Cancer Screening , by Product
3. Rest of the World Breast Cancer Screening , by Type
4. Rest of the World Breast Cancer Screening , by Gender
5. Rest of the World Breast Cancer Screening , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 29